Biotechgate Global Database ›
News in the Life Sciences Industry | |
| Results 1 - 8 out of 8 displayed. | |
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 23 Jul 2019 |
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer |
SINGAPORE, April 15, 2019 /PRNewswire/ -- Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies targeting solid tumors, today announced that it has entered into an agreement with Merck (known as MSD outside the US and... Read more ›› |
| By: PR Newswire Association LLC. - 16 Apr 2019 |
EB Research Partnership Announces the 3rd Annual Believe in Brady on April 7 in Houston |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 01 Apr 2019 |
GHIT Fund Announces Appointment of Catherine Ohura as New CEO and Executive Director |
TOKYO, March 28, 2019 /PRNewswire/ -- The Global Health Innovative Technology Fund (GHIT) today announced the appointment of Catherine Ohura as the organization's new CEO and Executive Director. Ohura brings depth and breadth of expertise and invaluable experience working for R&D and Commercial... Read more ›› |
| By: PR Newswire Association LLC. - 28 Mar 2019 |
GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis |
TOKYO, March 27, 2019 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 2.86 billion yen (US$25.8 million*) to support 10 partnerships to develop new lifesaving drugs, vaccines, and diagnostics for malaria, tuberculosis, dengue, leishmaniasis, and... Read more ›› |
| By: PR Newswire Association LLC. - 28 Mar 2019 |
GBT Reports Fourth Quarter and 2018 Results |
MONTEVIDEO, Uruguay, March 22, 2019 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q18 and 2018. Read more ›› |
| By: PR Newswire Association LLC. - 22 Mar 2019 |
| Related companies: BIOTON S.A. | Biosearch Life | Biofarm S.A. |
ESPN’s Scott Van Pelt to Host 2nd Annual Change for Charley on March 9 in Chicago |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 01 Mar 2019 |
EB Research Partnership Announces the 2nd Annual Plunge for Elodie on March 2 in Wellesley |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 21 Feb 2019 |
Partners
Upcoming Life Sciences Events
- September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)
